What is Revanex used for?

Revanex is indicated for Duodenal ulcer disease, Gastric ulcer, Gastro-esophageal reflux disease with esophagitis.

What development phase is Revanex in?

Revanex is FDA-approved (marketed).

What is the generic name of Revanex?

REVAPRAZAN is the generic (nonproprietary) name of Revanex.

Last reviewed 2026-04-20 · How we verify

Revanex (REVAPRAZAN)

FDA-approved active Small molecule Quality 20/100

At a glance

Generic name	REVAPRAZAN
Drug class	revaprazan
Target	Potassium-transporting ATPase
Modality	Small molecule
Therapeutic area	Gastroenterology
Phase	FDA-approved

Approved indications

Duodenal ulcer disease
Gastric ulcer
Gastro-esophageal reflux disease with esophagitis

Common side effects

No common side effects on file.

Key clinical trials

Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151' (PHASE1)
The Study Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151' (PHASE1)
A Study to Evaluate Safety, Tolerability, and PD of Tegoprazan on Healthy Male Volunteers (PHASE1)
Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD) (PHASE2)
Pharmacokinetic Drug Interaction Between Revaprazan and Itopride HCl in Healthy Male Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Revanex CI brief — competitive landscape report
Revanex updates RSS · CI watch RSS